Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H21N3O |
Molecular Weight | 259.3467 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
InChI
InChIKey=INDBQLZJXZLFIT-UHFFFAOYSA-N
InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
Primaquine is a oral medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. Primaquine is an alternative treatment for Pneumocystis pneumonia together with clindamycin. Primaquine is lethal to P. vivax and P. ovale in the liver stage, and also to P. vivax in the blood stage through its ability to do oxidative damage to the cell. However, the exact mechanism of action is not fully understood. Primaquine is well-absorbed in the gut and extensively distributed in the body without accumulating in red blood cells. Administration of primaquine with food or grapefruit juice increases its oral bioavailibity. In blood, about 20% of circulating primaquine is protein-bound, with preferential binding to the acute phase protein orosomucoid. With a half-life on the order of 6 hours, it is quickly metabolized by liver enzymes to carboxyprimaquine, which does not have anti-malarial activity. Common side effects of primaquine administration include nausea, vomiting, and stomach cramps. Primaquine phosphate is recommended only for the radical cure of vivax malaria, the prevention of relapse in vivax malaria, or following the termination of chloroquine phosphate suppressive therapy in an area where vivax malaria is endemic. Patients suffering from an attack of vivax malaria or having parasitized red blood cells should receive a course of chloroquine phosphate, which quickly destroys the erythrocytic parasites and terminates the paroxysm. Primaquine phosphate should be administered concurrently in order to eradicate the exoerythrocytic parasites in a dosage of 1 tablet (equivalent to 15 mg base) daily for 14 days.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3959 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21074425 |
7.5 µM [IC50] | ||
Target ID: CHEMBL1795182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900883 |
68.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AABLAQUIN Approved UseTreatment and prevention of p. vivax. Launch Date9.4668482E11 |
|||
Curative | PRIMAQUINE Approved UsePrimaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. Launch Date-5.661792E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
104 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
66 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
65 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
443 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
468 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027117/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4027118/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIMAQUINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Other AEs: Malaise, Headache... Other AEs: Malaise (1 patient) Sources: Headache (2 patients) Nausea (1 patient) Pyrexia (1 patient) Vomiting (1 patient) Dizziness (1 patient) Asthenia (1 patient) Pruritus (1 patient) Haemoglobin decreased (1 patient) Dyspepsia (1 patient) |
0.6 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.6 mg/kg, 1 times / day Co-administed with:: (artesunate) Sources: 50 mg |
unhealthy, adult n = 18 Health Status: unhealthy Condition: acute, symptomatic Plasmodium vivax malaria Age Group: adult Sex: unknown Population Size: 18 Sources: |
Disc. AE: Hematocrit decreased... AEs leading to discontinuation/dose reduction: Hematocrit decreased (4 patients) Sources: |
15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Other AEs: Malaise, Headache... Other AEs: Malaise (4 patients) Sources: Headache (2 patients) Nausea (1 patient) Decreased appetite (3 patients) Pyrexia (1 patient) Vomiting (1 patient) Dizziness (1 patient) Asthenia (1 patient) Arthralgia (1 patient) Muscle spasms (1 patient) Dyspnoea exertional (1 patient) Diarrhoea (1 patient) |
15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Other AEs: Malaise, Headache... Other AEs: Malaise (3 patients) Sources: Headache (1 patient) Nausea (2 patients) Pyrexia (1 patient) Vomiting (1 patient) Myalgia (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Asthenia | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Dizziness | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Dyspepsia | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Haemoglobin decreased | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Malaise | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Nausea | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Pruritus | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Pyrexia | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Vomiting | 1 patient | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Headache | 2 patients | 30 mg 1 times / day steady, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Hematocrit decreased | 4 patients Disc. AE |
0.6 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.6 mg/kg, 1 times / day Co-administed with:: (artesunate) Sources: 50 mg |
unhealthy, adult n = 18 Health Status: unhealthy Condition: acute, symptomatic Plasmodium vivax malaria Age Group: adult Sex: unknown Population Size: 18 Sources: |
Arthralgia | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Asthenia | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Diarrhoea | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Dizziness | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Dyspnoea exertional | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Muscle spasms | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Nausea | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Pyrexia | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Vomiting | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Headache | 2 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Decreased appetite | 3 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Malaise | 4 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 118 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 118 Sources: |
Headache | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Pyrexia | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Vomiting | 1 patient | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Myalgia | 2 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Nausea | 2 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Malaise | 3 patients | 15 mg 1 times / day steady, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: Plasmodium vivax parasite Age Group: adult Sex: M Population Size: 120 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.pmda.go.jp/drugs/2016/P20160309001/780069000_2800AMX00403000_I100_1.pdf#page=30 Page: (PMDA_I100_1 in Japanese) 29-30 |
minor [Km 37000 uM] | |||
Sources: https://www.pmda.go.jp/drugs/2016/P20160309001/780069000_2800AMX00403000_I100_1.pdf#page=30 Page: (PMDA_I100_1 in Japanese) 29-30 |
minor [Km 52000 uM] | |||
Sources: https://www.pmda.go.jp/drugs/2016/P20160309001/780069000_2800AMX00403000_I100_1.pdf#page=30 Page: (PMDA_I100_1 in Japanese) 29-30 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2016/P20160309001/780069000_2800AMX00403000_I100_1.pdf#page=30 Page: (PMDA_I100_1 in Japanese) 29-30 |
weak [Km 37000 uM] | |||
Sources: https://www.pmda.go.jp/drugs/2016/P20160309001/780069000_2800AMX00403000_I100_1.pdf#page=30 Page: (PMDA_I100_1 in Japanese) 29-30 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: (PMDA_A100_1 in Japanese) 10, (FDA label) 3 |
PubMed
Title | Date | PubMed |
---|---|---|
Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. | 1955 Aug |
|
Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. | 1968 Nov 21 |
|
Simultaneous drug reactions in the same patient. Chloroquine-Primaquine sensitivity. | 1970 Apr 27 |
|
Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. | 1988 Jun |
|
Isolation and characterization of rat lung Pneumocystis carinii gp120. | 1991 Nov-Dec |
|
Inhibitors of human immunodeficiency virus integrase. | 1993 Mar 15 |
|
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. | 1996 Dec |
|
Potential inhibitors of HIV integrase. | 1999 Apr-May |
|
Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. | 2001 May |
|
Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. | 2005 Aug |
|
Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. | 2005 Oct |
|
[Haemolysis due to primaquine in 3 cases]. | 2006 Feb 28 |
|
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. | 2006 May |
|
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. | 2006 Sep |
|
Development and validation of UPLC method for determination of primaquine phosphate and its impurities. | 2008 Jan 22 |
|
Formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet. | 2008 Oct |
|
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. | 2010 May |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria. | 2013 Jun 13 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16969059
Patients recieved 25 mg once daily for 7 days.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548031
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-ATC |
P01BA03
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
NDF-RT |
N0000175482
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
NCI_THESAURUS |
C271
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10043MIG
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
D011319
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
MVR3634GX1
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
4908
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
100000081655
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
201-987-2
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL506
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
90-34-6
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
27296
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
8405
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
DTXSID8023509
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
2266
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
MVR3634GX1
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
Primaquine
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
57152-47-3
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
SUPERSEDED | |||
|
C62071
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
6516
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
m9133
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
Primaquine
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
8687
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB01087
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
218
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)